Forbion Closes Third Fund, 'Agnostic' On When To Invest
This article was originally published in Clinica
Forbion Capital Partners has conducted the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of €183m ($207m). Despite the Netherlands-based venture firm closing its last fund - FCF II - in 2010 when the investment climate was less friendly, Forbion's investment strategy remains much the same, according to managing partner Sander Slootweg.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.